Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran autogene vaccine with Merck's KEYTRUDA, fueling investor optimism despite no new announcements. Moderna expects an interim analysis from its Phase 3 melanoma trial later in 2026, which could further impact the stock. Peer BioNTech showed minimal movement, indicating the market is focused on Moderna's specific vaccine program rather than the broader mRNA cancer vaccine sector.
Moderna trades at USD 159.22 on Pluang, up 9.34% as of Sep 17, 2026 21:02 WIB, showing strong investor interest. BioNTech and Novavax also rise, with BioNTech up 3.70% at USD 99.38 and Novavax up 5.88% at USD 9.90. Pluang order activity favors buying Novavax at 100% and Moderna at 67%, reflecting confidence in these health sector stocks.
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
